Egalet Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Egalet (EGLT) Tops Q2 EPS by 6c, Revenues Miss
August 8, 2018 6:19 AM EDTEgalet (NASDAQ: EGLT) reported Q2 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $7.99 million.
"In the second quarter, we continued to grow our commercial products and improve our payer coverage," said Bob Radie, president and chief executive officer of Egalet. "Since the beginning of the year, we have had five commercial market access wins which we believe should improve patient access to both SPRIX Nasal Spray and ARYMO ER."
Cash Position: As of June 30, 2018, Egalet had cash, marketable securities... More